CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 124 enrolled
Drug / intervention
Toripalimab +5 moredrug
Likely dose
Toripalimab 240 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04844385
NCT04844385Phase 2Unknown
CompareCT.gov

A Prospective Single-arm Phase Ⅱ Study of Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Sun Yat-sen University·interventional·Posted Apr 14, 2021·Updated Feb 9, 2024

In Brief

A Phase 2 clinical trial evaluating Toripalimab, Paclitaxel-albumin, and 4 other interventions for Esophageal Squamous Cell Carcinoma. Targeting 124 participants across 1 site.

Detailed Summary

This Phase II non-randomized study is to determine the efficacy and toxicity of neoadjuvant toripalimab plus chemotherapy followed by chemoradiotherapy for locally advanced unresectable esophageal squamous cell carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Squamous Cell Carcinoma
CountriesChina
Collaborators--

Timeline

Phase 2UnknownOverdue
202120222023202420252026
First PostedApr 14, 2021
Enrollment StartFeb 20, 2021
Primary CompletionDec 20, 2024
TodayJul 1, 2026
Enrollment to primary: 3.8 yearsPosted 5.2 years ago

Interventions

Toripalimabdrug

Toripalimab 240 mg, d1, Q3w for two cycles

Paclitaxel-albumindrug

Paclitaxel-albumin 260 mg/m2, d1, Q3w for two cycles

Nedaplatindrug

Nedaplatin 75mg/m2, d1, Q3w for two cycles

radiation therapy at a total dose 60 Gyradiation

Radiation therapy at a total dose 60 Gy

Capecitabinedrug

Capecitabine 1000 mg/m2, bid, d1-14, q3w during radiotherapy

radiation therapy at a total dose 50 Gyradiation

Radiation therapy at a total dose 50 Gy